## Phillip A Doerfler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1228909/publications.pdf

Version: 2024-02-01

933447 1058476 15 688 10 14 citations g-index h-index papers 17 17 17 824 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Dual function NFI factors control fetal hemoglobin silencing in adult erythroid cells. Nature Genetics, 2022, 54, 874-884.	21.4	13
2	Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing. Nature Genetics, 2021, 53, 895-905.	21.4	305
3	Genetic therapies for the first molecular disease. Journal of Clinical Investigation, 2021, 131, .	8.2	17
4	Activation of $\hat{l}^3$ -globin gene expression by GATA1 and NF-Y in hereditary persistence of fetal hemoglobin. Nature Genetics, 2021, 53, 1177-1186.	21.4	21
5	Regulation of Fetal Hemoglobin Expression By the VHL-HIF1α Oxygen Sensing System. Blood, 2021, 138, 574-574.	1.4	3
6	AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice. Molecular Therapy - Methods and Clinical Development, 2019, 15, 194-203.	4.1	14
7	Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Advances, 2019, 3, 3379-3392.	5.2	121
8	CRISPR-Cas9 Genome Editing of $\hat{i}^3$ -Globin Promoters in Human Hematopoietic Stem Cells to Induce Erythrocyte Fetal Hemoglobin for Treatment of $\hat{i}^2$ -Hemoglobinopathies. Blood, 2019, 134, 2066-2066.	1.4	1
9	The DNA Methylation Maintenance Protein UHRF1 Regulates Fetal Globin Expression Independent of HBG Promoter DNA Methylation. Blood, 2018, 132, 410-410.	1.4	0
10	Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy - Methods and Clinical Development, 2016, 3, 15053.	4.1	44
11	Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. Human Gene Therapy, 2016, 27, 43-59.	2.7	44
12	Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Plant Biotechnology Journal, 2015, 13, 1023-1032.	8.3	51
13	BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease. Clinical Immunology, 2015, 158, 140-147.	3.2	13
14	Copackaging of Multiple Adeno-Associated Viral Vectors in a Single Production Step. Human Gene Therapy Methods, 2014, 25, 269-276.	2.1	4
15	Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent. PLoS ONE, 2014, 9, e98336.	2.5	25